These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16027440)

  • 21. Quantifying angiogenesis in VEGF-enhanced tissue-engineered bladder constructs by dynamic contrast-enhanced MRI using contrast agents of different molecular weights.
    Cheng HL; Wallis C; Shou Z; Farhat WA
    J Magn Reson Imaging; 2007 Jan; 25(1):137-45. PubMed ID: 17139634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.
    Li KL; Wilmes LJ; Henry RG; Pallavicini MG; Park JW; Hu-Lowe DD; McShane TM; Shalinsky DR; Fu YJ; Brasch RC; Hylton NM
    J Magn Reson Imaging; 2005 Oct; 22(4):511-9. PubMed ID: 16161072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detecting vascular-targeting effects of the hypoxic cytotoxin tirapazamine in tumor xenografts using magnetic resonance imaging.
    Bains LJ; Baker JH; Kyle AH; Minchinton AI; Reinsberg SA
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):957-65. PubMed ID: 19480975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Limitations of single slice dynamic contrast enhanced MR in pharmacokinetic modeling of bone sarcomas.
    Toms AP; White LM; Kandel R; Bleakney RR; Noseworthy M; Lee S; Blackstein ME; Wunder J
    Acta Radiol; 2009 Jun; 50(5):512-20. PubMed ID: 19431058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlations between dynamic contrast-enhanced magnetic resonance imaging-derived measures of tumor microvasculature and interstitial fluid pressure in patients with cervical cancer.
    Haider MA; Sitartchouk I; Roberts TP; Fyles A; Hashmi AT; Milosevic M
    J Magn Reson Imaging; 2007 Jan; 25(1):153-9. PubMed ID: 17173303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reproducibility of the aortic input function (AIF) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the kidneys in a volunteer study.
    Mendichovszky IA; Cutajar M; Gordon I
    Eur J Radiol; 2009 Sep; 71(3):576-81. PubMed ID: 19004588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.
    Rosen MA; Schnall MD
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):770s-776s. PubMed ID: 17255308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular imaging of antiangiogenic agents.
    Rehman S; Jayson GC
    Oncologist; 2005 Feb; 10(2):92-103. PubMed ID: 15709211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.
    Dowlati A; Robertson K; Cooney M; Petros WP; Stratford M; Jesberger J; Rafie N; Overmoyer B; Makkar V; Stambler B; Taylor A; Waas J; Lewin JS; McCrae KR; Remick SC
    Cancer Res; 2002 Jun; 62(12):3408-16. PubMed ID: 12067983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.
    Redman BG; Esper P; Pan Q; Dunn RL; Hussain HK; Chenevert T; Brewer GJ; Merajver SD
    Clin Cancer Res; 2003 May; 9(5):1666-72. PubMed ID: 12738719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies.
    Roberts C; Issa B; Stone A; Jackson A; Waterton JC; Parker GJ
    J Magn Reson Imaging; 2006 Apr; 23(4):554-63. PubMed ID: 16506143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.
    Ricart AD; Ashton EA; Cooney MM; Sarantopoulos J; Brell JM; Feldman MA; Ruby KE; Matsuda K; Munsey MS; Medina G; Zambito A; Tolcher AW; Remick SC
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):959-70. PubMed ID: 21305290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3D dynamic contrast-enhanced MRI of rectal carcinoma at 3T: correlation with microvascular density and vascular endothelial growth factor markers of tumor angiogenesis.
    Zhang XM; Yu D; Zhang HL; Dai Y; Bi D; Liu Z; Prince MR; Li C
    J Magn Reson Imaging; 2008 Jun; 27(6):1309-16. PubMed ID: 18504761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis.
    Xu PJ; Yan FH; Wang JH; Lin J; Ji Y
    J Magn Reson Imaging; 2009 Feb; 29(2):341-9. PubMed ID: 19161186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic Gd-DTPA enhanced MRI as a surrogate marker of angiogenesis in tissue-engineered bladder constructs: a feasibility study in rabbits.
    Cheng HL; Chen J; Babyn PS; Farhat WA
    J Magn Reson Imaging; 2005 Apr; 21(4):415-23. PubMed ID: 15778952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of hypoxia in human cervical carcinoma xenografts by dynamic contrast-enhanced magnetic resonance imaging.
    Ellingsen C; Egeland TA; Gulliksrud K; Gaustad JV; Mathiesen B; Rofstad EK
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):838-45. PubMed ID: 19215820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients.
    Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Horsman MR
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):859-66. PubMed ID: 18164835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of response to treatment using DCE-MRI: the relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis.
    Walker-Samuel S; Leach MO; Collins DJ
    Phys Med Biol; 2006 Jul; 51(14):3593-602. PubMed ID: 16825751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.
    Medved M; Karczmar G; Yang C; Dignam J; Gajewski TF; Kindler H; Vokes E; MacEneany P; Mitchell MT; Stadler WM
    J Magn Reson Imaging; 2004 Jul; 20(1):122-8. PubMed ID: 15221817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.